Rafferty Asset Management LLC reduced its stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 20.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 819,115 shares of the biotechnology company’s stock after selling 213,246 shares during the quarter. Rafferty Asset Management LLC owned about 0.53% of Adaptimmune Therapeutics worth $3,489,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Lindbrook Capital LLC raised its stake in Adaptimmune Therapeutics by 310.6% during the 2nd quarter. Lindbrook Capital LLC now owns 6,610 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 5,000 shares in the last quarter. HighTower Advisors LLC acquired a new stake in Adaptimmune Therapeutics during the 2nd quarter worth $64,000. Hunter Associates Investment Management LLC acquired a new stake in Adaptimmune Therapeutics during the 1st quarter worth $84,000. Janney Montgomery Scott LLC acquired a new stake in Adaptimmune Therapeutics during the 1st quarter worth $159,000. Finally, Credit Agricole S A acquired a new stake in Adaptimmune Therapeutics during the 2nd quarter worth $128,000. Hedge funds and other institutional investors own 71.48% of the company’s stock.
Several brokerages recently commented on ADAP. Barclays began coverage on shares of Adaptimmune Therapeutics in a research note on Friday, May 28th. They set an “underweight” rating and a $4.00 price target on the stock. Jonestrading reissued a “buy” rating and set a $15.00 price objective on shares of Adaptimmune Therapeutics in a research report on Monday. Mizuho began coverage on shares of Adaptimmune Therapeutics in a research report on Thursday, September 9th. They set a “hold” rating and a $9.00 price objective on the stock. Finally, SVB Leerink raised their price objective on shares of Adaptimmune Therapeutics from $6.00 to $7.00 and gave the stock a “market perform” rating in a research report on Monday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.75.
Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its earnings results on Sunday, August 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.01. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $0.60 million. Adaptimmune Therapeutics had a negative net margin of 2,391.97% and a negative return on equity of 45.65%. As a group, sell-side analysts forecast that Adaptimmune Therapeutics plc will post -0.72 earnings per share for the current fiscal year.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Featured Story: Dual Listing What You Need to Know
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.